Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Clinical trial NCT04553770 · RECRUITING

Trial details

NCT number: NCT04553770
Sponsor: Jonsson Comprehensive Cancer Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Early-stage Breast Cancer Hormone Receptor Positive Breast Carcinoma Invasive Breast Cancer Stage II Breast Cancer Stage IIA Breast Cancer Stage IIB Breast Cancer Stage III Breast Cancer

Start date: 2020-10-09
Primary completion: 2026-12-31
Enrollment: 88

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.